Glaxo’s HPV vaccine shown effective for more than four years

Study shows HPV vaccine that can prevent up to 70% of cervical cancers is long-lasting.

BY Matthew Van Atta

April 07 2006 12:00 AM ET

An ongoing study
of GlaxoSmithKline’s experimental human
papillomavirus vaccine Ceravix, which aims to prevent
infection with HPV strains linked to the development
of cervical cancer, shows that the vaccine is
effective against the virus for 4 1/2 years after
vaccination, BBC News reports. The vaccine targets HPV
strains 16 and 18, which are linked to about 70% of
all cervical cancer cases. Previous studies have show the
vaccine is 100% effective in blocking infection with those
strains. Researchers say the vaccine also may prevent
infection with HPV strains 31 and 45, which would make
the shot effective against 80% of cervical cancer
cases.

The ongoing study
shows that women who took Ceravix maintained high
levels of antibodies against HPV strains 16 and 18 for up to
4 1/2 years after being inoculated. Researchers
say the study will continue to gauge how long
protection against HPV lasts and if booster shots may
be needed to provide optimum protection.

Glaxo has
submitted Ceravix for European approval and expects to file
for U.S. approval with the Food and Drug
Administration in the second half of the year. The FDA
in February granted priority review status to the
vaccine. (The Advocate)

Tags: Health

AddThis

READER COMMENTS ()

Quantcast